Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $3,522,000.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 100,000 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares in the company, valued at $983,271.96. The trade was a 78.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Price Performance

HIMS stock opened at $40.36 on Friday. The stock has a market cap of $8.82 billion, a price-to-earnings ratio of 91.72 and a beta of 1.35. The company has a 50 day simple moving average of $30.02 and a 200 day simple moving average of $23.12. Hims & Hers Health, Inc. has a 1 year low of $9.14 and a 1 year high of $44.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.04) EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Hims & Hers Health during the fourth quarter worth about $18,048,000. Arizona State Retirement System boosted its position in Hims & Hers Health by 23.4% during the 4th quarter. Arizona State Retirement System now owns 51,327 shares of the company’s stock worth $1,241,000 after buying an additional 9,723 shares during the period. Victory Capital Management Inc. increased its position in Hims & Hers Health by 1.9% in the 4th quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock valued at $1,271,000 after acquiring an additional 1,002 shares during the period. Keybank National Association OH bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $237,000. Finally, Cornerstone Investment Partners LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $240,000. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on HIMS shares. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price target for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Needham & Company LLC increased their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.